Page 6 - El Chaar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Qetaifan Projects, the leading Qatari real estate development company owned by Katara Hospitality, and Dar Al Arkan, the realty major in Saudi Arabia, have

Quara Holding has announced a strategic partnership with CRMNEXT, World’s No. 1 CRM and digital customer experience platform in banking and financial services, bringing world-class digital transformation solutions to Saudi Arabia.

21 dicembre 2020 07:17 Fonte: Adnkronos #architettura-e-edilizia Quara Holding invests in digital innovation and integration across all its business sectors RIYADH, Saudi Arabia, Dec. 20, 2020 /PRNewswire/ -- Quara Holding, a Saudi-based investment entity operating for over 25 years and present in 11 countries, unveiled today its new identity and business strategy. It represents a new phase in Saudi business and aims to achieve digital integration between its subsidiary companies in the financial, real estate, and technology sectors. Quara Holding leverages its advanced digital capabilitie...

USI Insurance Services Acquires Venneberg Insurance USI Insurance Services Acquires Venneberg Insurance VALHALLA, N.Y., Dec. 14, 2020 — USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement consulting, today announced the acquisition of Sitka, Alaska-based Venneberg Insurance. Founded in 1984, Venneberg Insurance is an independent risk management and insurance agency serving businesses and individuals throughout Southeast Alaska. All of the agency’s employees, including Mike Venneberg, owner and principal, will be joining USI. Terms of the ...

Tarsier Pharma’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in Uveitis TEL-AVIV, Israel, Dec. 17, 2020 — Tarsier Pharma (doing business as Tarsius Pharma Ltd.), a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and received important feedback on its trial design and program for its TRS01 Phase 3 program in...